Cervical cancer assay
This article was originally published in The Gray Sheet
German diagnostics firm mtm laboratories launches its CE-marked Cervatec assay in Europe for detecting cervical cell protein biomarkers. Used with conventional Pap testing, Cervatec is more than twice as sensitive as Pap tests alone in cervical cancer screening, the firm said Feb. 5. Unlike available molecular human papillomavirus (HPV) tests such as Qiagen/Digene's Hybrid Capture, Cervatec indicates the presence of the disease, not just an elevated risk, mtm CEO Peter Pack said. The firm could not disclose whether it would seek FDA approval for the test
You may also be interested in...
CPAC shoots for $45 million: Start-up firm Compact Particle Acceleration Corp. (CPAC) plans to raise approximately $45 million in three phases to help develop a "state-of-the-art," compact, intensity-modulated proton therapy system for cancer treatment featuring a dielectric-wall accelerator, according to co-development partner and investor TomoTherapy Inc. The latter firm will contribute certain intellectual property to CPAC and has the option to acquire from CPAC rights to the medical applications of the accelerator in the future. The accelerator technology, which resulted from defense-related research at Lawrence Livermore National Laboratory, is "distinct from current particle accelerator technology in that energies of 200 MeV are expected to be achieved within a relatively compact structure that fits in a standard therapy treatment room," explains TomoTherapy, a NASDAQ-traded Madison, Wis., firm that makes the Hi Art radiation therapy system for cancer treatment. CPAC anticipates closing phase one of its fundraising effort within the next several months
Celltrion has announced plans to add a third biopharmaceutical facility and a new global biotechnology research center at the Korean firm’s existing site in Songdo, Incheon, as the firm also revealed record third-quarter financial results.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.